Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection

Elena Sbrana, Robert Jordan, Dennis E. Hruby, Rosa I. Mateo, Shu Yuan Xiao, Marina Siirin, Patrick C. Newman, Amelia P A Travassos Da Rosa, Robert B. Tesh

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Efficacy of the new antipoxvirus compound ST-246 was evaluated as treatment of monkeypox (MPX) virus infection in a ground squirrel model of the disease. Ground squirrels were given a lethal dose of MPX virus and were then treated orally at various times post-inoculation (pi) with 100 mg/kg/day of ST-246. Morbidity and mortality, clinical laboratory results, viral load, and pathology of placebo and treatment groups were compared. All animals that started treatment with ST-246 on days 0, 1, 2, and 3 pi survived lethal challenge with MPX virus; 67% of animals treated on day 4 pi also survived. In contrast, 100% of the placebo group died. Most of the ST-246-treated animals showed no evidence of clinical disease or alteration of baseline clinical laboratory values and had minimal histopathologic changes. These results suggest that ST-246 is a promising candidate for early treatment of severe orthopoxvirus infection.

Original languageEnglish (US)
Pages (from-to)768-773
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume76
Issue number4
StatePublished - Apr 2007

Fingerprint

Orthopoxvirus
Monkeypox virus
Infection
Sciuridae
Placebos
Therapeutics
Virus Diseases
Viral Load
ST-246
Pathology
Morbidity
Mortality

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Sbrana, E., Jordan, R., Hruby, D. E., Mateo, R. I., Xiao, S. Y., Siirin, M., ... Tesh, R. B. (2007). Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. American Journal of Tropical Medicine and Hygiene, 76(4), 768-773.

Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. / Sbrana, Elena; Jordan, Robert; Hruby, Dennis E.; Mateo, Rosa I.; Xiao, Shu Yuan; Siirin, Marina; Newman, Patrick C.; Travassos Da Rosa, Amelia P A; Tesh, Robert B.

In: American Journal of Tropical Medicine and Hygiene, Vol. 76, No. 4, 04.2007, p. 768-773.

Research output: Contribution to journalArticle

Sbrana, E, Jordan, R, Hruby, DE, Mateo, RI, Xiao, SY, Siirin, M, Newman, PC, Travassos Da Rosa, APA & Tesh, RB 2007, 'Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection', American Journal of Tropical Medicine and Hygiene, vol. 76, no. 4, pp. 768-773.
Sbrana, Elena ; Jordan, Robert ; Hruby, Dennis E. ; Mateo, Rosa I. ; Xiao, Shu Yuan ; Siirin, Marina ; Newman, Patrick C. ; Travassos Da Rosa, Amelia P A ; Tesh, Robert B. / Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. In: American Journal of Tropical Medicine and Hygiene. 2007 ; Vol. 76, No. 4. pp. 768-773.
@article{fd880d20c4c8495285477257e3fb0335,
title = "Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection",
abstract = "Efficacy of the new antipoxvirus compound ST-246 was evaluated as treatment of monkeypox (MPX) virus infection in a ground squirrel model of the disease. Ground squirrels were given a lethal dose of MPX virus and were then treated orally at various times post-inoculation (pi) with 100 mg/kg/day of ST-246. Morbidity and mortality, clinical laboratory results, viral load, and pathology of placebo and treatment groups were compared. All animals that started treatment with ST-246 on days 0, 1, 2, and 3 pi survived lethal challenge with MPX virus; 67{\%} of animals treated on day 4 pi also survived. In contrast, 100{\%} of the placebo group died. Most of the ST-246-treated animals showed no evidence of clinical disease or alteration of baseline clinical laboratory values and had minimal histopathologic changes. These results suggest that ST-246 is a promising candidate for early treatment of severe orthopoxvirus infection.",
author = "Elena Sbrana and Robert Jordan and Hruby, {Dennis E.} and Mateo, {Rosa I.} and Xiao, {Shu Yuan} and Marina Siirin and Newman, {Patrick C.} and {Travassos Da Rosa}, {Amelia P A} and Tesh, {Robert B.}",
year = "2007",
month = "4",
language = "English (US)",
volume = "76",
pages = "768--773",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "4",

}

TY - JOUR

T1 - Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection

AU - Sbrana, Elena

AU - Jordan, Robert

AU - Hruby, Dennis E.

AU - Mateo, Rosa I.

AU - Xiao, Shu Yuan

AU - Siirin, Marina

AU - Newman, Patrick C.

AU - Travassos Da Rosa, Amelia P A

AU - Tesh, Robert B.

PY - 2007/4

Y1 - 2007/4

N2 - Efficacy of the new antipoxvirus compound ST-246 was evaluated as treatment of monkeypox (MPX) virus infection in a ground squirrel model of the disease. Ground squirrels were given a lethal dose of MPX virus and were then treated orally at various times post-inoculation (pi) with 100 mg/kg/day of ST-246. Morbidity and mortality, clinical laboratory results, viral load, and pathology of placebo and treatment groups were compared. All animals that started treatment with ST-246 on days 0, 1, 2, and 3 pi survived lethal challenge with MPX virus; 67% of animals treated on day 4 pi also survived. In contrast, 100% of the placebo group died. Most of the ST-246-treated animals showed no evidence of clinical disease or alteration of baseline clinical laboratory values and had minimal histopathologic changes. These results suggest that ST-246 is a promising candidate for early treatment of severe orthopoxvirus infection.

AB - Efficacy of the new antipoxvirus compound ST-246 was evaluated as treatment of monkeypox (MPX) virus infection in a ground squirrel model of the disease. Ground squirrels were given a lethal dose of MPX virus and were then treated orally at various times post-inoculation (pi) with 100 mg/kg/day of ST-246. Morbidity and mortality, clinical laboratory results, viral load, and pathology of placebo and treatment groups were compared. All animals that started treatment with ST-246 on days 0, 1, 2, and 3 pi survived lethal challenge with MPX virus; 67% of animals treated on day 4 pi also survived. In contrast, 100% of the placebo group died. Most of the ST-246-treated animals showed no evidence of clinical disease or alteration of baseline clinical laboratory values and had minimal histopathologic changes. These results suggest that ST-246 is a promising candidate for early treatment of severe orthopoxvirus infection.

UR - http://www.scopus.com/inward/record.url?scp=34249742507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249742507&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 768

EP - 773

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 4

ER -